vs
渤健（BIIB）与普洛斯（PLD）财务数据对比。点击上方公司名可切换其他公司
渤健的季度营收约是普洛斯的1.0倍（$2.3B vs $2.3B），普洛斯净利率更高（62.1% vs -2.1%，领先64.3%），普洛斯同比增速更快（2.4% vs -7.1%），过去两年普洛斯的营收复合增速更高（7.3% vs -0.2%）
渤健是总部位于美国马萨诸塞州剑桥市的跨国生物技术企业，专注于神经系统疾病治疗领域。公司核心产品包括用于多发性硬化症的特菲达、万立能等多款药物，以及治疗脊髓性肌萎缩症的诺西那生钠、治疗弗里德赖希共济失调的Skyclarys，致力于为神经疾病和罕见病患者提供创新疗法。
普洛斯是一家总部位于美国加利福尼亚州旧金山的不动产投资信托企业，专注于物流设施的投资与运营。公司2011年由AMB地产集团与原普洛斯合并成立，是全球规模最大的工业地产企业。截至2025年，运营超1.5万英亩土地及6000余栋物业，为全球客户提供高品质物流仓储解决方案。
BIIB vs PLD — 直观对比
营收规模更大
BIIB
是对方的1.0倍
$2.3B
营收增速更快
PLD
高出9.5%
-7.1%
净利率更高
PLD
高出64.3%
-2.1%
两年增速更快
PLD
近两年复合增速
-0.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $2.3B | $2.3B |
| 净利润 | $-48.9M | $1.4B |
| 毛利率 | 78.3% | — |
| 营业利润率 | -2.5% | 72.2% |
| 净利率 | -2.1% | 62.1% |
| 营收同比 | -7.1% | 2.4% |
| 净利润同比 | -118.3% | 9.5% |
| 每股收益（稀释后） | $-0.35 | $1.50 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIIBPLD
| Q4 25 | $2.3B | $2.3B | ||
| Q3 25 | $2.5B | $2.2B | ||
| Q2 25 | $2.6B | $2.2B | ||
| Q1 25 | $2.4B | $2.1B | ||
| Q4 24 | $2.5B | $2.2B | ||
| Q3 24 | $2.5B | $2.0B | ||
| Q2 24 | $2.5B | $2.0B | ||
| Q1 24 | $2.3B | $2.0B |
净利润BIIBPLD
| Q4 25 | $-48.9M | $1.4B | ||
| Q3 25 | $466.5M | $764.3M | ||
| Q2 25 | $634.8M | $571.2M | ||
| Q1 25 | $240.5M | $593.0M | ||
| Q4 24 | $266.7M | $1.3B | ||
| Q3 24 | $388.5M | $1.0B | ||
| Q2 24 | $583.6M | $861.3M | ||
| Q1 24 | $393.4M | $585.7M |
毛利率BIIBPLD
| Q4 25 | 78.3% | — | ||
| Q3 25 | 73.4% | — | ||
| Q2 25 | 77.1% | — | ||
| Q1 25 | 74.1% | — | ||
| Q4 24 | 76.2% | — | ||
| Q3 24 | 74.1% | — | ||
| Q2 24 | 77.8% | — | ||
| Q1 24 | 76.3% | — |
营业利润率BIIBPLD
| Q4 25 | -2.5% | 72.2% | ||
| Q3 25 | 22.0% | 42.5% | ||
| Q2 25 | 28.1% | 41.8% | ||
| Q1 25 | 12.8% | 41.1% | ||
| Q4 24 | 11.9% | 64.6% | ||
| Q3 24 | 18.3% | 61.4% | ||
| Q2 24 | 28.3% | 51.0% | ||
| Q1 24 | 20.3% | 36.8% |
净利率BIIBPLD
| Q4 25 | -2.1% | 62.1% | ||
| Q3 25 | 18.4% | 34.5% | ||
| Q2 25 | 24.0% | 26.2% | ||
| Q1 25 | 9.9% | 27.7% | ||
| Q4 24 | 10.9% | 58.1% | ||
| Q3 24 | 15.8% | 49.4% | ||
| Q2 24 | 23.7% | 42.9% | ||
| Q1 24 | 17.2% | 29.9% |
每股收益（稀释后）BIIBPLD
| Q4 25 | $-0.35 | $1.50 | ||
| Q3 25 | $3.17 | $0.82 | ||
| Q2 25 | $4.33 | $0.61 | ||
| Q1 25 | $1.64 | $0.63 | ||
| Q4 24 | $1.82 | $1.38 | ||
| Q3 24 | $2.66 | $1.08 | ||
| Q2 24 | $4.00 | $0.92 | ||
| Q1 24 | $2.70 | $0.63 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $1.1B |
| 总债务越低越好 | $6.3B | $35.0B |
| 股东权益账面价值 | $18.3B | $53.2B |
| 总资产 | $29.4B | $98.7B |
| 负债/权益比越低杠杆越低 | 0.34× | 0.66× |
8季度趋势，按日历期对齐
现金及短期投资BIIBPLD
| Q4 25 | — | $1.1B | ||
| Q3 25 | — | $1.2B | ||
| Q2 25 | — | $1.1B | ||
| Q1 25 | — | $671.1M | ||
| Q4 24 | — | $1.3B | ||
| Q3 24 | — | $780.9M | ||
| Q2 24 | — | $598.3M | ||
| Q1 24 | — | $500.6M |
总债务BIIBPLD
| Q4 25 | $6.3B | $35.0B | ||
| Q3 25 | $6.3B | $35.3B | ||
| Q2 25 | $6.3B | $34.7B | ||
| Q1 25 | $4.5B | $32.3B | ||
| Q4 24 | $6.3B | $30.9B | ||
| Q3 24 | $4.5B | $32.3B | ||
| Q2 24 | $6.3B | $29.9B | ||
| Q1 24 | $6.3B | $29.6B |
股东权益BIIBPLD
| Q4 25 | $18.3B | $53.2B | ||
| Q3 25 | $18.2B | $52.6B | ||
| Q2 25 | $17.6B | $52.7B | ||
| Q1 25 | $17.0B | $53.5B | ||
| Q4 24 | $16.7B | $54.0B | ||
| Q3 24 | $16.4B | $53.1B | ||
| Q2 24 | $15.9B | $53.3B | ||
| Q1 24 | $15.2B | $53.2B |
总资产BIIBPLD
| Q4 25 | $29.4B | $98.7B | ||
| Q3 25 | $29.2B | $98.3B | ||
| Q2 25 | $28.3B | $97.7B | ||
| Q1 25 | $28.0B | $96.0B | ||
| Q4 24 | $28.0B | $95.3B | ||
| Q3 24 | $28.3B | $95.9B | ||
| Q2 24 | $26.8B | $93.5B | ||
| Q1 24 | $26.6B | $93.3B |
负债/权益比BIIBPLD
| Q4 25 | 0.34× | 0.66× | ||
| Q3 25 | 0.35× | 0.67× | ||
| Q2 25 | 0.36× | 0.66× | ||
| Q1 25 | 0.27× | 0.60× | ||
| Q4 24 | 0.38× | 0.57× | ||
| Q3 24 | 0.28× | 0.61× | ||
| Q2 24 | 0.40× | 0.56× | ||
| Q1 24 | 0.41× | 0.56× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $511.9M | $1.2B |
| 自由现金流经营现金流 - 资本支出 | $468.0M | — |
| 自由现金流率自由现金流/营收 | 20.5% | — |
| 资本支出强度资本支出/营收 | 1.9% | — |
| 现金转化率经营现金流/净利润 | — | 0.83× |
| 过去12个月自由现金流最近4个季度 | $2.1B | — |
8季度趋势，按日历期对齐
经营现金流BIIBPLD
| Q4 25 | $511.9M | $1.2B | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $160.9M | $1.2B | ||
| Q1 25 | $259.3M | $1.2B | ||
| Q4 24 | $760.9M | $1.3B | ||
| Q3 24 | $935.6M | $1.4B | ||
| Q2 24 | $625.8M | $1.1B | ||
| Q1 24 | $553.2M | $1.1B |
自由现金流BIIBPLD
| Q4 25 | $468.0M | — | ||
| Q3 25 | $1.2B | — | ||
| Q2 25 | $134.3M | — | ||
| Q1 25 | $222.2M | — | ||
| Q4 24 | $721.6M | — | ||
| Q3 24 | $900.6M | — | ||
| Q2 24 | $592.3M | — | ||
| Q1 24 | $507.3M | — |
自由现金流率BIIBPLD
| Q4 25 | 20.5% | — | ||
| Q3 25 | 48.4% | — | ||
| Q2 25 | 5.1% | — | ||
| Q1 25 | 9.1% | — | ||
| Q4 24 | 29.4% | — | ||
| Q3 24 | 36.5% | — | ||
| Q2 24 | 24.0% | — | ||
| Q1 24 | 22.1% | — |
资本支出强度BIIBPLD
| Q4 25 | 1.9% | — | ||
| Q3 25 | 1.8% | — | ||
| Q2 25 | 1.0% | — | ||
| Q1 25 | 1.5% | — | ||
| Q4 24 | 1.6% | — | ||
| Q3 24 | 1.4% | — | ||
| Q2 24 | 1.4% | — | ||
| Q1 24 | 2.0% | — |
现金转化率BIIBPLD
| Q4 25 | — | 0.83× | ||
| Q3 25 | 2.73× | 1.89× | ||
| Q2 25 | 0.25× | 2.17× | ||
| Q1 25 | 1.08× | 1.96× | ||
| Q4 24 | 2.85× | 1.04× | ||
| Q3 24 | 2.41× | 1.43× | ||
| Q2 24 | 1.07× | 1.26× | ||
| Q1 24 | 1.41× | 1.80× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIIB
| Products | $1.7B | 73% |
| Tysabri Product | $244.5M | 11% |
| AVONEX | $119.2M | 5% |
| SKYCLARYS | $88.9M | 4% |
| Alzheimers Collaboration | $47.1M | 2% |
| IMRALDI | $43.5M | 2% |
| TECFIDERA | $36.9M | 2% |
| PLEGRIDY | $24.7M | 1% |
| QALSODY | $7.8M | 0% |
| BYOOVIZ | $4.3M | 0% |
PLD
| Real Estate Operations Segment | $2.0B | 88% |
| Unconsolidated Co Investment Ventures | $131.7M | 6% |
| Other | $82.6M | 4% |
| Strategic Capital Segment | $49.9M | 2% |
